From the Avidity acquisition to HARBOR’s Phase III failure — a retrospective examination of clinical evidence, medical governance, and capital allocation
BBIU Strategic Red Team | Strategic Report
October 30, 2026
Executive Summary
On October 27, 2026, Novartis reported a $1.94 billion impairment associated with delpacibart etedesiran (del-desiran), an investigational treatment acquired through its approximately $12 billion purchase of Avidity Biosciences.
The impairment followed the failure of the Phase III HARBOR trial to demonstrate statistically significant improvement in its primary endpoint, video Hand Opening Time (vHOT), in patients with myotonic dystrophy type 1 (DM1).
The financial consequences extended beyond the impaired clinical asset. Novartis recognized an additional $600 million provision associated with a long-term manufacturing supply agreement whose expected capacity utilization had changed following the HARBOR results.
Together, these charges amounted to $2.54 billion.
The impairment was a non-cash accounting charge. The manufacturing provision represents estimated contractual obligations with uncertain future cash outflows. Neither figure should be mistaken for an equivalent new cash payment during the quarter.
More importantly, the outcome raises a question that extends beyond Novartis:
What could an independent scientific and strategic review have identified before the acquisition — and could those findings have changed the decision, its valuation, or the company's exposure to clinical failure?
This report examines the evidence available before the acquisition announcement in October 2025, distinguishes it from subsequent clinical findings, and identifies questions that warranted explicit consideration before committing capital.
The central issue is not whether the failure of HARBOR could have been predicted with certainty.
It is whether the acquisition's underlying clinical assumptions were sufficiently challenged before they became financial commitments.
1. The Financial Event: When Clinical Uncertainty Becomes Balance-Sheet Exposure
Novartis announced its agreement to acquire Avidity Biosciences in October 2025 and completed the transaction on February 27, 2026.
The transaction added three late-stage neuromuscular programs and Avidity's antibody-oligonucleotide conjugate (AOC) technology platform.
According to Novartis's third-quarter 2026 financial report, the preliminary purchase price allocation assigned:
$7.48 billion to del-desiran, targeting DM1.
Approximately $3.8 billion collectively to the acquired FSHD and DMD programs.
Approximately $1.4 billion to goodwill.
Del-desiran therefore represented approximately two-thirds of the value allocated to the three clinical IPR&D assets.
In September 2026, HARBOR failed to meet its primary endpoint.
Novartis subsequently reduced del-desiran's carrying value from $7.48 billion to $5.54 billion, recognizing a $1.94 billion impairment.
The company's financial disclosures provide an especially revealing sensitivity analysis.
Holding other assumptions constant, a ten-percentage-point change in the probability of technical and regulatory success would alter the estimated recoverable value of del-desiran by approximately $1 billion.
A 10% change in projected net sales would change that value by approximately $700 million.
These sensitivities were disclosed after the clinical failure. They are not presented here as calculations that were publicly available before the acquisition.
Nevertheless, they illustrate the financial significance of the assumptions embedded in pharmaceutical asset valuations.
The questions are straightforward.
How thoroughly were the clinical assumptions underpinning del-desiran's valuation challenged?
Were the uncertainties surrounding the primary endpoint, pharmacodynamic response, and probability of clinical success adequately reflected in the acquisition decision?
And were alternative transaction structures or downside protections considered?
The public record does not disclose Novartis's internal due-diligence deliberations. It therefore cannot establish that these questions were ignored.
It does, however, establish that the financial consequences of the clinical outcome were substantial.
2. What Was Known Before the Acquisition?
A retrospective evaluation must begin with a strict distinction between information available before the decision and evidence generated afterward.
By October 2025, Avidity had reported molecular activity and encouraging functional observations from its MARINA and MARINA-OLE studies.
Del-desiran was designed to reduce DMPK messenger RNA using a small interfering RNA (siRNA) conjugated to an antibody targeting transferrin receptor 1 (TfR1).
In DM1, expanded CUG repeats in DMPK RNA cause pathological interactions with RNA-binding proteins, particularly MBNL, disrupting the normal splicing of multiple transcripts involved in muscular function.
Reducing DMPK RNA could potentially restore aspects of this molecular process.
Avidity had demonstrated evidence of muscle delivery and DMPK reduction, accompanied by changes in splicing-related biomarkers.
These observations represented meaningful pharmacological progress.
However, demonstrating molecular activity is not equivalent to demonstrating clinically meaningful functional recovery.
The clinical development strategy required several successive assumptions to hold:
Delivery of the siRNA to skeletal muscle would provide adequate exposure to the relevant cellular compartments.
Suppression of DMPK RNA would be sufficiently sustained and effective against the disease-causing transcript.
Molecular correction would restore enough downstream biological activity to influence muscular function.
Functional improvement would become measurable within the selected treatment period.
The treatment effect would be sufficiently large and consistent to demonstrate superiority over placebo.
Each assumption represented a separate source of uncertainty.
Avidity's earlier studies provided evidence supporting parts of this sequence, but they had not established every link through confirmatory clinical testing.
The central due-diligence question was therefore not whether del-desiran possessed pharmacological activity.
It was whether the available evidence justified the magnitude and timing of the expected clinical benefit.
3. HARBOR: The Critical Transition From Molecular Evidence to Functional Efficacy
The Phase III HARBOR trial (NCT06411288) enrolled 159 patients with DM1.
The study evaluated del-desiran against placebo, using vHOT as its primary endpoint.
vHOT measures the time required for the hand to open after contraction and provides a quantitative assessment of myotonia.
The choice has a valid physiological rationale.
Myotonia is a characteristic manifestation of DM1, and correcting abnormal RNA processing could theoretically improve muscular relaxation.
However, the measurement also introduces a critical translational question.
An observed difficulty in opening the hand can reflect more than a single molecular mechanism.
The patient's functional performance may be influenced by abnormal muscle excitability, weakness, structural deterioration, disease severity, and variability in the assessment procedure.
These factors do not make vHOT invalid.
They do make it necessary to establish that the expected pharmacological effect is sufficiently related to the endpoint being measured.
This distinction is especially relevant in DM1, a chronic multisystem disease in which some muscular abnormalities may have developed over many years.
Improvement in RNA processing may occur earlier than the restoration of clinically measurable function.
Moreover, correction of an underlying molecular disturbance does not necessarily reverse established muscular damage.
The appropriate question is not whether vHOT was scientifically unreasonable.
It is whether the early clinical evidence was sufficiently robust to predict a reproducible treatment effect in a randomized pivotal trial.
In its October 2025 acquisition presentation, Novartis identified vHOT as the primary endpoint and stated that the study design was aligned with the FDA, EMA, and other regulatory authorities.
Regulatory alignment is important.
But alignment on a trial design does not guarantee that the investigational treatment will produce a sufficiently large effect on the selected endpoint.
The Change From Week 30 to Week 54
The original HARBOR registration specified assessment of its primary endpoint through Week 30.
The evaluation period was subsequently extended to Week 54.
Novartis's October 2025 investor presentation already described a 54-week placebo-controlled study. Avidity later disclosed that the relevant protocol amendment was submitted to the FDA in January 2026.
A longer evaluation period can be scientifically justified for a treatment intended to modify a slowly progressive disease.
However, extending the assessment period raises further questions about the expected temporal relationship between pharmacological activity and functional improvement.
What evidence supported the original assessment window?
What new considerations justified its extension?
Were the assumptions concerning effect size, variability, and statistical power reconsidered?
And what did the change imply about confidence in the expected time course of clinical benefit?
There may have been appropriate scientific answers to all these questions.
The public record does not establish the adequacy of the internal assessments or identify who approved each decision.
For an independent Red Team, however, these questions would have been central to reviewing the development strategy.
4. Pharmacology: A Valuable Technology With Unresolved Clinical Translation
One of the most important distinctions in the Avidity acquisition concerns the value of the AOC delivery platform versus the efficacy of del-desiran itself.
The technology attempts to solve a longstanding problem in RNA therapeutics: delivering active oligonucleotides to tissues beyond the liver.
By conjugating an anti-TfR1 antibody with siRNA, the platform enables delivery into muscle and subsequent pharmacological activity.
This is a meaningful technological achievement.
However, in DM1, the disease-causing expanded DMPK RNA is substantially retained within the nucleus.
RNA interference acts predominantly through intracellular RISC-associated mechanisms.
This makes the relationship between tissue delivery, intracellular distribution, and effective degradation of the pathogenic nuclear RNA particularly important.
The distinction is critical:
Drug concentration in muscle tissue does not directly establish the amount of pharmacologically active siRNA reaching the pathogenic RNA target within myonuclei.
The earlier molecular evidence supported a mechanism of action but did not fully resolve the relationship between intracellular exposure and sustained clinical response.
Nor did it establish how much downstream correction would be required to produce measurable muscular improvement.
What Subsequent Research Added
A detailed molecular analysis published in Molecular Therapy in March 2026 examined del-desiran's effects on DMPK RNA and splicing abnormalities.
The investigators identified 412 disease-associated splicing events and highlighted 93 events meeting their criteria for correction following treatment.
This finding is consistent with molecular activity.
However, it does not establish that 93 events were completely normalized, nor that all remaining events were unchanged or worsened.
The study did not provide a complete, symmetrical quantitative classification of all 412 events into improved, unchanged, and worsened categories under equivalent statistical criteria.
The analysis also included in-vitro experiments showing reduction of DMPK RNA in nuclear fractions after direct siRNA transfection.
Those experiments provide evidence that the siRNA component can affect nuclear RNA. They do not directly demonstrate the concentration of active siRNA delivered to human myonuclei after intravenous administration of the complete antibody conjugate.
These findings refine the mechanistic questions raised by the development program.
Importantly, the detailed publication appeared after the October 2025 acquisition announcement.
It cannot legitimately be treated as public evidence that Novartis should have considered at the time of that announcement.
The questions themselves, however — intracellular target engagement, sustained suppression, and the quantitative relationship between molecular activity and clinical response — were scientifically relevant before the acquisition.
The failure of HARBOR does not eliminate the technological value of AOC delivery.
It demonstrates why platform capability and product-specific clinical efficacy must be valued separately.
5. Safety: A Known Risk Before the Acquisition
In September 2022, the FDA imposed a partial clinical hold on new enrollment in MARINA following a serious neurological adverse event in a participant receiving 4 mg/kg.
The event involved bilateral thalamic ischemia with subsequent hemorrhagic transformation.
According to Avidity's regulatory disclosures, the investigator initially classified the event as related to the investigational drug.
Avidity subsequently stated that, following investigation and consultation with independent experts, it had not identified a plausible biological mechanism linking the event to the treatment.
The partial hold was lifted in October 2024.
These facts must be distinguished.
The initial investigator assessment establishes a suspected relationship.
The sponsor's subsequent assessment challenges that causal interpretation.
The FDA's decision to lift the hold allowed development to proceed; it did not constitute a public determination that the event was unrelated to treatment.
The available public documentation also does not establish whether the patient experienced permanent neurological impairment.
A scientifically rigorous acquisition review should have examined the complete safety narrative, subsequent neurological findings, risk mitigation measures, and the relevance of chronic exposure.
This does not imply that a single serious adverse event should automatically terminate a development program.
It means that a potentially consequential safety signal belongs explicitly in the clinical risk assessment.
6. Medical and Clinical Governance: Where Does Responsibility Reside?
The HARBOR protocol originated at Avidity before the acquisition.
That fact does not eliminate the acquiring company's responsibility for evaluating the program.
Avidity's 2025 corporate disclosures identify Sarah Boyce as President and CEO, Steven Hughes as Chief Medical Officer, and Kathleen Gallagher as Chief Program Officer.
Hughes publicly presented the HARBOR pivotal design in March 2024.
At Novartis, Shreeram Aradhye has served as President, Development and Chief Medical Officer since 2022.
Novartis announced the acquisition while that executive structure was in place.
In January 2026, Novartis also announced that Stephen Moran would become Managing Director of Avidity following completion of the transaction.
These are documented leadership roles, not evidence of individual misconduct.
The public record establishes who held relevant responsibilities and who presented particular programs. It does not disclose every internal review, recommendation, approval, or disagreement.
The governance question is therefore institutional.
How were clinical development, Medical Affairs, regulatory strategy, scientific due diligence, and capital allocation connected during the acquisition decision?
An acquisition of this scale should not be evaluated solely through its scientific promise or projected commercial opportunity.
The underlying evidence must be tested against alternative interpretations, potential failure mechanisms, and the financial consequences of those failures.
The relevant challenge is whether independent internal review mechanisms were sufficiently empowered to question the assumptions upon which the transaction depended.
7. MONALEESA and NATALEE: Are There Broader Governance Questions?
The Avidity case should not be interpreted in isolation from Novartis's broader clinical development record.
However, comparisons must distinguish genuine methodological controversies from successful trials that generated scientific disagreement.
MONALEESA: Clinical Evidence and Promotional Interpretation
The MONALEESA program investigated ribociclib, a CDK4/6 inhibitor, in advanced breast cancer.
Its trials demonstrated clinically meaningful efficacy, including overall survival benefits.
The program should not be characterized as a clinical failure.
Nevertheless, a British pharmaceutical self-regulatory proceeding concerning promotional materials for Kisqali identified breaches involving misleading presentation of certain MONALEESA-7 findings.
The issue concerned the interpretation and communication of evidence in relation to treatment combinations, rather than falsification of trial results.
This illustrates a distinct governance responsibility: ensuring that scientifically valid results are communicated accurately within their evidentiary and regulatory boundaries.
NATALEE: Endpoint Maturity, Censoring, and Benefit-Risk Interpretation
NATALEE investigated adjuvant ribociclib in early breast cancer.
The trial demonstrated a statistically significant improvement in invasive disease-free survival, supporting FDA approval in September 2024.
However, the FDA identified concerns about the maturity of the initial analysis. Only approximately 20% of patients had completed the planned three-year treatment period at the relevant interim analysis.
The agency requested additional follow-up, and the benefit persisted at the final iDFS analysis.
Independent researchers subsequently questioned whether censoring patterns could affect the interpretation of the treatment benefit.
These concerns must be balanced against the regulatory conclusions and subsequent evidence.
On October 23, 2026, investigators reported a favorable overall survival signal at six years, with a hazard ratio of 0.809 and an absolute survival difference of approximately 2.1 percentage points.
That analysis was prespecified but descriptive, with nominal statistical significance.
The newer evidence strengthens the case for ribociclib's clinical benefit while leaving questions about long-term risk-benefit interpretation and the handling of incomplete follow-up worthy of careful examination.
What These Cases Do — and Do Not — Establish
MONALEESA, NATALEE, and HARBOR do not demonstrate a common clinical failure.
They concern different diseases, development strategies, endpoints, and outcomes.
Nor can three selected cases establish a systematic organizational deficiency without examining the larger portfolio, including successful programs.
They do, however, justify a broader question:
Are the mechanisms used to challenge clinical assumptions, assess evidence maturity, supervise development decisions, and communicate uncertainty sufficiently consistent across the organization?
That is a legitimate question of medical and clinical governance.
It is not, on the present evidence, a finding of systematic misconduct or negligent trial management.
8. The Pre-Acquisition Red Team: What Could Have Been Challenged?
An independent Red Team engaged before the acquisition would not have needed to predict that HARBOR would fail.
Its responsibility would have been to determine which assumptions mattered most to the transaction, what evidence supported them, and how the investment decision should respond if those assumptions proved incorrect.
A structured assessment could have concentrated on five decision tests.
Test 1 — Clinical Translation
Does the available molecular evidence support the expected magnitude of functional improvement?
The team would examine the relationship between DMPK reduction, splicing correction, patient heterogeneity, disease duration, and functional outcomes.
The purpose would be to distinguish demonstrated biological activity from projected therapeutic benefit.
Test 2 — Endpoint and Statistical Robustness
What effect size and variability were assumed when designing HARBOR?
How well were those assumptions supported by randomized data?
How sensitive was the probability of success to the selected endpoint, assessment period, population, and missing-data assumptions?
Regulatory alignment would be considered relevant but not sufficient to resolve those questions.
Test 3 — Pharmacological Exposure and Safety
Was there adequate evidence that the selected dose and treatment interval produced sustained suppression of the pathogenic transcript?
What did muscle biopsy data actually demonstrate?
How were the serious neurological event and remaining safety uncertainties incorporated into the risk assessment?
The goal would not be to declare the drug ineffective or unsafe, but to identify what remained unproven.
Test 4 — Valuation and Downside Exposure
How much of the acquisition valuation depended on del-desiran's pivotal success?
How would a delayed launch, narrower indication, additional trial requirement, or negative HARBOR outcome affect expected value?
Were manufacturing commitments and development obligations appropriately aligned with clinical milestones?
Could alternative transaction terms have reduced downside exposure without sacrificing access to the platform and other programs?
The feasibility of any restructuring would depend on the commercial negotiations and available alternatives.
Test 5 — Independent Decision Governance
Were clinical, statistical, regulatory, and commercial assumptions challenged independently?
Were dissenting scientific interpretations documented and escalated?
Did the investment committee receive a clear distinction between established evidence, assumptions, and unresolved risks?
And were the conditions that would justify changing or abandoning the transaction explicitly defined?
These are not abstract questions.
Each can influence acquisition valuation, deal structure, development commitments, or the decision to proceed.
9. Could an Independent Review Have Prevented the Impairment?
The available evidence does not permit that conclusion.
Novartis may have considered the relevant risks and concluded that acquiring the broader Avidity portfolio and AOC platform justified accepting the exposure.
The company also acquired two additional neuromuscular programs whose clinical and commercial prospects must be assessed separately.
Moreover, a negative pivotal result is not proof that the original investment decision was irrational.
A technically sound development program can fail even when its risks have been appropriately evaluated.
Nevertheless, the acquisition illustrates an important distinction.
Risk identification does not require outcome prediction.
An independent Red Team can add value even if the final investment decision remains unchanged.
Its contribution lies in making the decision more explicit:
Which assumptions are critical?
Which are supported by confirmatory evidence?
Which remain dependent on extrapolation?
How much capital is exposed to each assumption?
What alternative decisions are available?
What evidence would justify reconsideration?
The possible commercial value is not confined to avoiding a transaction.
It can include changing the price, negotiating protections, reducing contingent commitments, modifying the development strategy, or preserving financial flexibility.
No specific amount of avoided loss is claimed in this retrospective assessment.
10. The Larger Lesson: Scientific Expertise Is Not the Same as Independent Challenge
Large pharmaceutical companies possess extensive scientific, medical, regulatory, and financial expertise.
Their challenge is not necessarily a shortage of information.
It is that major decisions require integrating evidence produced by specialized teams operating under different objectives, incentives, and time horizons.
Clinical developers seek to advance promising treatments.
Regulatory specialists seek an acceptable development and approval pathway.
Business development teams evaluate strategic opportunities.
Financial teams translate expectations into valuations.
Senior management must reconcile these perspectives before committing capital.
Each function may perform its assigned responsibilities competently.
Yet important assumptions can remain insufficiently challenged at the point where those perspectives converge.
An independent Red Team has a different responsibility.
It is not required to defend the development program, justify the acquisition thesis, or preserve the commercial forecast.
Its task is to identify the assumptions most capable of changing the decision and test them against the strongest available contrary evidence.
That independence is particularly valuable when a scientific uncertainty carries material financial consequences.
11. BBIU Strategic Red Team: The Decision Before the Commitment
The Novartis–Avidity case demonstrates why clinical development risk and capital allocation cannot be evaluated independently.
A molecular mechanism may be scientifically credible without producing adequate clinical efficacy.
An endpoint may be acceptable to regulators without being sufficiently sensitive to detect the anticipated benefit.
A technology platform may retain significant value even when an individual clinical program misses its primary endpoint.
And an acquisition may offer strategic benefits while exposing the buyer to concentrated clinical and financial risk.
These distinctions should be established before capital is committed, not merely reconstructed after an adverse outcome.
BBIU Strategic Red Team examines consequential decisions through independent scientific, regulatory, operational, and financial analysis.
The objective is not to guarantee success or predict every failure.
It is to test the assumptions that determine whether a decision remains justified under uncertainty.
The most valuable intervention may occur before a protocol is finalized, before a licensing agreement is signed, or before an acquisition price becomes irreversible.
A $1.94 billion impairment is a financial outcome.
The clinical assumptions embedded in the decision are the more important subject of investigation.
The question for executives, investment committees, and boards is therefore not simply what went wrong at Novartis.
It is:
Which assumptions underlying your next major decision have not yet been independently challenged — and how much capital depends on them?
BBIU Strategic Red Team
Challenge Your Assumptions. Before You Decide.
Primary Sources and References
Acquisition and financial disclosures
Novartis. Novartis agrees to acquire Avidity Biosciences. October 26, 2025. Official acquisition announcement.
Novartis. Acquisition of Avidity — Investor Presentation. October 27, 2025. Particularly slides 14–15, covering MARINA-OLE and HARBOR. Original presentation.
Novartis. Condensed Interim Financial Report, Third Quarter and Nine Months 2026. Notes 3 and 10, pages 27–28 and 41–43. Original financial report.
Novartis. HARBOR Phase III study update. September 8, 2026. Official clinical announcement.
Clinical development and safety
Avidity Biosciences. Transforming Myotonic Dystrophy: Global Phase III HARBOR Trial and MARINA-OLE Data. March 4, 2024. SEC-filed investor presentation.
ClinicalTrials.gov. HARBOR — NCT06411288. Official trial registration.
ClinicalTrials.gov. MARINA-OLE — NCT05479981. Official trial registration.
Avidity Biosciences. Form 8-K describing the neurological SAE and the partial clinical hold. March 2023. SEC filing.
Avidity Biosciences. Form 10-K for the year ended December 31, 2025. Includes disclosure of the HARBOR protocol amendment submitted in January 2026. SEC filing.
Kwan TT, et al. Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study. Molecular Therapy. 2026;34:3872–3884. DOI: 10.1016/j.ymthe.2026.03.013. Full text.
Governance and related clinical programs
Avidity Biosciences. 2025 Proxy Statement. Executive officers and corporate governance. SEC filing.
Novartis. Shreeram Aradhye — President, Development and Chief Medical Officer. Official executive biography.
UK Prescription Medicines Code of Practice Authority. AUTH/3256/10/19 — Anonymous v Novartis: Promotion of Kisqali. Completed August 2020. Official regulatory case.
U.S. FDA. Approval summary: Ribociclib in high-risk early breast cancer. September 17, 2024. FDA announcement.
Slamon DJ, et al. Overall survival with adjuvant ribociclib: Six-year follow-up of NATALEE. Annals of Oncology. Published online October 23, 2026. DOI: 10.1016/j.annonc.2026.10.1288. PubMed.
Methodology and Disclosure
This report is an independent retrospective assessment prepared from publicly available corporate disclosures, SEC filings, clinical trial registrations, regulatory records, and scientific publications.
The pre-acquisition analysis is limited to information available by the October 2025 acquisition announcement. Evidence published afterward is identified separately and used only to assess subsequent developments.
The report does not claim access to Novartis's or Avidity's confidential due-diligence materials, internal trial governance records, clinical study reports, or investment committee deliberations.
Named executives are identified solely through documented professional roles and periods of responsibility. Their inclusion does not imply individual negligence, misconduct, or personal approval of specific decisions absent supporting evidence.
The report does not assert that independent review would necessarily have prevented the acquisition, changed HARBOR's clinical outcome, or avoided the impairment.
BBIU is independent of Novartis and Avidity. The analysis is not commissioned by either company and does not constitute investment advice.
© 2026 BBIU Strategic Red Team. Independent strategic analysis.
